belantamab mafodotin
gsk
['dreamm,9', 'belantamab,mafodotin', 'dreamm', 'belantamab']
congress l #ash22 daniel lowther reveals that at progression, bcma levels were detectable in 98% of patients in dreamm-1 and 98.9% of patients in dreamm-2. no evidence was found to suggest that bcma expression is completely lost after treatment with belantamab mafodotin
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma